Wednesday, July 8, 2026

Drug profile · INN

argatroban

argatroban (ARGATROBAN) is a thrombin inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved NMPA: clinical trials
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — argatroban
US status
approved
Class
Route
INJECTION
Patents
0
Programs
1
Data quality
0.89

Quick answer

argatroban (ARGATROBAN) is a thrombin inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN argatroban
Brand ARGATROBAN
Mechanism Thrombin inhibitor
Target Prothrombin
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Thrombin inhibitor

Primary target: Prothrombin

Approval history

Authority Status Date
FDA approved
NMPA clinical trials

Pipeline programs

  1. 0.9% sodium chloride Phase 2 · First People's Hospital · Kidney Disease, Chronic

Related & competitor drugs

  1. bivalirudin Blood and blood forming organs (B01)
  2. dabigatran etexilate mesylate Thrombin inhibitor
  3. desirudin recombinant Thrombin inhibitor
  4. desirudin Blood and blood forming organs (B01)
  5. lepirudin Blood and blood forming organs (B01)
  6. ximelagatran Thrombin inhibitor

Frequently asked questions

What is argatroban?

argatroban (ARGATROBAN) is a thrombin inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for argatroban?

ARGATROBAN is a marketed brand name for argatroban. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of argatroban?

argatroban has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.